U.S. Ends $600M Moderna Bird Flu Vaccine Contract

THURSDAY, May 29, 2025 (HealthDay News) — The U.S. government has canceled a $600 million contract with Moderna to develop a vaccine for bird flu and other dangerous flu strains, raising concerns among experts.

The deal, forged under the Biden administration, aimed to prepare for future flu pandemics by funding Moderna’s work on a fast-acting vaccine using mRNA technology, STAT News reported.

Moderna had already started a Phase 1/2 trial of its bird flu (H5N1) vaccine and reported strong early results.

The company said nearly 98% of participants developed protective antibody levels three weeks after receiving two doses, STAT News added.

“While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,” Moderna CEO Stéphane Bancel said in a statement.

“These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats,” he added.

But Andrew Nixon, U.S. Health and Human Services (HHS) communications director, told STAT News problems had emerged.

“After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,” he said.

Nixon pointed to safety concerns with mRNA vaccines and said the government wouldn’t repeat what he described as mistakes made during COVID-19 vaccine efforts.

However, global data show that mRNA vaccines, including those used during the COVID pandemic, have been generally safe.

Some cases of heart inflammation (myocarditis) were seen in teen males, but the risk was also present after COVID infection itself. Those cases have since declined, the U.S. Centers for Disease Control and Prevention (CDC) reported last month.

“This is a huge mistake,” said Rick Bright, former head of the Biomedical Advanced Research and Development Authority (BARDA), the agency that gave Moderna the funds.

“Much time, investment, and goodwill will be lost because of this short-sighted and politically charged decision,” he said.

Dr. Jesse Goodman, a former U.S. Food and Drug Administration (FDA) chief scientist, predicted drug companies will be wary of working with the U.S. government in the future.

“Unless there is a clear reason for terminating the funding, not only will we be left less prepared, potentially risking the lives of millions, but vaccine and other innovators will question the reliability of U.S. government investments and partnerships, and may think twice about engaging in public health efforts for which there is no clear reward in terms of a marketed product,” Goodman said.

The canceled funding was aimed at helping Moderna develop vaccines for flu strains that could trigger a pandemic — such as H5N1 and H7N9, STAT News reported.